AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
49.04
-1.15 (-2.29%)
Real-time:   9:32AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 48.97 - 49.05
52 week 42.68 - 53.45
Open 48.97
Vol / Avg. 78,915.00/1.87M
Mkt cap 61.40B
P/E 10.86
Div/yield 1.90/5.71
EPS 4.52
Shares 1.25B
Beta 0.61
Inst. own 9%
Jun 18, 2013
AstraZeneca PLC at Citi European Healthcare Conference
Jun 13, 2013
AstraZeneca PLC at Goldman Sachs Healthcare Conference
Jun 1, 2013
AstraZeneca PLC ASCO Briefing Investor & Analyst Conference Call
May 29, 2013
AstraZeneca PLC at EBD Group ChinaBio Partnering Forum
Apr 25, 2013
Q1 2013 AstraZeneca PLC Earnings Conference Call
Apr 22, 2013
AstraZeneca PLC at Biotechnology Industry Organization (BIO) International Convention
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 15.85% 22.62%
Operating margin 21.88% 29.13%
EBITD margin - 48.06%
Return on average assets 7.67% 11.90%
Return on average equity 17.62% 26.81%
Employees 51,700 -
Carbon Disclosure Rating - 73/100

Address

2 Kingdom Street, Paddington
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In August 2012, Alliance Pharma plc�s subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands. In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 53
Bio & Compensation  - Reuters
Simon Jonathan Lowth Chief Financial Officer, Executive Director
Age: 51
Bio & Compensation  - Reuters
Lynn Tetrault Executive Vice President - Human Resources and Corporate Affairs
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Marc Dunoyer Executive Vice President, Global Portfolio & Product Strategy
Bio & Compensation  - Reuters
Paul Hudson Executive Vice President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Briggs Morrison Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters